Ruben Mesa, MD

Ruben Mesa, MD, discusses crucial data from the COMFORT studies that show ruxolitinib's benefit in patients with myelofibrosis.

Ruben Mesa, MD, shares highlights from his presentation on the role of JAK inhibitors in myelofibrosis during the first annual Texas Virtual MPN Workshop and Meeting.

Ruben Mesa, MD, discusses the role of JAK inhibitors, which are currently being investigated in patients with myelofibrosis. He also spoke to what the future of this treatment landscape may be.

Ruben Mesa, MD, discusses the current challenges in the treatment landscape for researchers treating myelofibrosis (MF) and how a greater understanding of why patients relapse will help investigators overcome these challenges.

Ruben Mesa, MD, discusses the role of ruxolitinib and fedratinib, first-generation JAK inhibitors, as treatment of patients with myelofibrosis.

Ruben Mesa, MD, discusses the current state of the treatment landscape for patients with myeloproliferative neoplasms.

Ruben Mesa, MD, director of the Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center,&nbsp;gives advice on using the JAK inhibitors ruxolitinib and fedratinib in the community setting for patients with intermediate-risk myelofibrosis.<br /> &nbsp;

Ruben Mesa, MD, discusses his experience with fedratinib since its FDA approval for the treatment of patients with myelofibrosis. The agent is compared across trials with ruxolitinib, which has been approved for several years in this space.

Ruben Mesa, MD, discusses the results from a reanalysis of the phase II JAKARTA-2 study in patients with myelofibrosis (MF) who received a previous treatment of ruxolitinib (Jakafi) and failed treatment.

Ruben Mesa, MD, director, UT Health San Antonio Cancer Center, discusses NCCN guideline updates in polycythemia vera and essential thrombocythemia.